AEROGEN PHARMA LIMITED

Aerogen Pharma is an Irish specialty pharmaceutical company dedicated to developing novel aerosol therapies for life‑threatening respiratory disease in pre‑term infants. As the drug‑development arm of the Aerogen Group – the global leader in high‑performance aerosol drug delivery – Aerogen leverages a patented technology platform that enhances the world’s #1 hospital nebuliser range, creating a new standard for delivering inhaled medicines directly to the lungs.

The company’s flagship programme, AeroFact™ Phase 3, is evaluating a non‑invasive pulmonary surfactant treatment for respiratory distress syndrome in pre‑term babies. The aim is to reduce the risks associated with the current invasive surfactant administration, minimise interruptions to non‑invasive ventilation, and lessen patient discomfort. Aerogen’s expertise spans inhalation therapeutics, advanced nebuliser technology and the translation of these innovations into clinical trials and commercial products.

Headquartered in Galway, Ireland, Aerogen Pharma also operates development sites in San Mateo, California and Morrisville, North Carolina, enabling close collaboration with international partners and clinical networks while maintaining its Irish roots.